Stage IV Lung Cancer AJCC v8 Clinical Trials in Brighton, Michigan

5 studies are recruiting for stage iv lung cancer ajcc v8 in Brighton, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

   This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell sign…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton, Michigan

   Locations

   603 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04181060 on ClinicalTrials.gov

2. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

   This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and …

   Stage

   Phase 3

   Ages

   70 and older

   Site

   Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton, Michigan

   Locations

   324 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06096844 on ClinicalTrials.gov

3. Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

   This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) an…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton, Michigan

   Locations

   454 in total

   Run by

   SWOG Cancer Research Network

   See if you can join NCT05642572 on ClinicalTrials.gov

4. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

   This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period o…

   Stage

   Phase 2

   Ages

   Any age

   Site

   Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton, Michigan

   Locations

   266 in total

   Run by

   SWOG Cancer Research Network

   See if you can join NCT06031688 on ClinicalTrials.gov

5. Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

   This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cem…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton, Michigan

   Locations

   386 in total

   Run by

   SWOG Cancer Research Network

   See if you can join NCT06616584 on ClinicalTrials.gov